The nation of Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on confidential information.
This rejection became public after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesperson has since clarified that the US was demanding access to biological samples for scientific study and commercial purposes but was not willing to guarantee the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued negotiations to reach a agreement agreeable to all parties so the country's critical HIV programme can continue.
Wider Implications
This rejection follows a similar case in Kenya, where a court blocked a related health funding agreement following concerns were raised about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government agreements to boost openness and accountability.
Based on reports, Sixteen nations in Africa have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"In essence, our country would provide the basic resources for scientific discovery without any certainty that the end products would be available to our population should a future disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were upending frameworks previously set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is designed to guarantee that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how subsequent collaboration could be designed in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
Medical experts stated it understood the government's concerns, but suggested that negotiations should continue considering a large portion of the nation's Aids initiatives relied on foreign aid.
"Where technical issues exist, such as those relating to information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it commented.
The halted deal emphasises the ongoing debate between accepting vital international aid and safeguarding a country's data in an ever more data-driven world.